Drug to Work against Neurodegenerative Disease in Experimental Stage
It has been said that GlaxoSmithKline is working on a drug that can work quite well against the neurodegenerative problems like Alzheimer's, Parkinson's disease.
For now, the research at a preliminary stage, said study researchers. Their drug, GSK2606414, is able to block the disruption that causes neurodegenerative disease. The study has been published in the U. S. journal Science Translational Medicine.
While explaining the entire procedure, study researchers have affirmed that certain diseases starts spreading by developing rogue proteins in the brain. In order to stop the same, the brain goes in to the mode called as the unfolded protein response.
The mechanism is such that it would not allow the brain to make new proteins. But the rogue proteins that are present in the brain try to stop the mechanism from getting switched off. In this scenario, neither, neither misshapen proteins nor normal protein cells are made.
Study researchers are developing a drug that will work by ensuring that production of normal proteins, which is vital for the survival for brain cells. "We're still a long way from a usable drug for humans -- this compound had serious side effects", affirmed Giovanna Mallucci, a professor of toxicology. Other researchers have appreciated the efforts.
Following up on an unprecedented press release by...Read More
The French people are used to the presidential...Read More
Newly elected French President Emmanuel Macron said...Read More
At 39 years of age, Emmanuel Macron is the bold,...Read More
The first round of voting in the French...Read More